A 72-year-old man with a history of inferior vena cava (IVC) filter (TrapEaseTM, Cordis) implantation for deep venous thrombus 3 years ago was admitted to our emergency department in shock. His systolic blood pressure was 60 mmHg, and his heart rate was 112 beats/min. Marked venous congestion appeared only in his lower body ( Figure 1A) . Computed tomography showed the collapsed IVC ( Figure 1B) . To maintain his blood pressure, fluid resuscitation from upper extremity was performed. Emergency venography revealed almost total occlusion of the IVC filter with a large thrombus (Figure 2A) . Aspiration thrombectomy with an 8-Fr right Judkins guiding catheter was performed, and large red 
A 72-year-old man with a history of inferior vena cava (IVC) filter (TrapEaseTM, Cordis) implantation for deep venous thrombus 3 years ago was admitted to our emergency department in shock. His systolic blood pressure was 60 mmHg, and his heart rate was 112 beats/min. Marked venous congestion appeared only in his lower body ( Figure 1A) . Computed tomography showed the collapsed IVC ( Figure 1B) . To maintain his blood pressure, fluid resuscitation from upper extremity was performed. Emergency venography revealed almost total occlusion of the IVC filter with a large thrombus ( Figure 2A) . Aspiration thrombectomy with an 8-Fr right Judkins guiding catheter was performed, and large red thrombi were aspirated ( Figure 2C ). Adjunctive transcatheter thrombolysis with urokinase (240,000 IU) was attempted for residual thrombi. Five days after the procedure, adequate venous flow was achieved ( Figure 2B ). During 2 years of follow-up care, the patient has not experienced additional clinical events. The IVC filter is a widely used and effective device for reduction of pulmonary embolism; however, the use of IVC filter causes the increase of deep-vein thrombosis and has no beneficial impact on long-term mortality (1, 2) . Therefore, the efficacy and safety of the permanent IVC filter are still under debate. Although deep-vein thrombosis including filter thrombosis after the IVC filter implantation is not rare, IVC filter thromboocclusion is a rare and potentially fatal complication. Kalva et al. reported that only 0.7% (2/270) of their patients who were implanted with TrapEase filters had near-total IVC occlusion, and none was symptomatic (3) . In the present case, the patient was in shock with skin lesions on the lower body.
We speculate that these differences in the clinical presentations of IVC filter issues are due to whether IVC filter occlusion occurs suddenly or not. In acute IVC filter thrombosis, sudden fall in venous return contributes to hemodynamic deterioration, resulting in life-threatening condition. Therefore, some cases involving acute IVC filter thrombosis will require emergent invasive treatment to maintain venous return. On the other hand, most cases in chronic IVC filter thrombosis are asymptomatic. Paton et al. suggested that chronic caval occlusion is likely the result of intimal overgrowth and slow, allowing for the development of collateral flow and therefore more likely to be asymptomatic (4) . In these chronic conditions, invasive procedures to recanalize occluded IVC will be not required. The optimal treatment strategy for acute IVC filter occlusion is not fully established. Treatment options following filter thrombosis may include transcatheter thrombolytic therapy, intravenous thrombolytic therapy, or mechanical thrombectomy (5-7). In the present case, early diagnosis by in-Heart, Lung and Vessels. 2015, Vol. 7
Cite this article as: Higashi H, Yoshii T, Inaba S, Morofuji T, Morioka H, Saito M, Sumimoto T. Life-threatening shock due to inferior vena cava fi lter thrombosis. Heart, Lung and Vessels. 2015; 7(3): 263-265. Source of Support: Nil. Disclosures: None declared. spection of the skin promoted further examination and treatment. Transcatheter thrombolysis following aspiration thromborectomy was successfully performed without complications. Further investigation is needed to clarify which strategies are most effective to treat IVC fi lter thrombosis.
